pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

MIRUM

USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view MIRUM jobs →

News

  • Mirum plans FDA submission for hepatitis D treatment as competition brews
    Mirum’s hepatitis D treatment has succeeded in the second of two pivotal trials. Now comes the next challenge: competing with rivals in a growing market. The Phase 3 trial, called AZURE-4, enrolled…
    endpoints · 6d ago
  • Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA run
    Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late-stage trial of its antiviral monoclonal antibody brelovitug.
    fiercebiotech · 7d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 7d ago
  • Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
    Vir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.
    biospace · 7d ago
  • Vir hepatitis D drug succeeds in first pivotal study
    A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
    biopharma_dive · 7d ago
  • Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead
    Vir Biotechnology’s phase 3 trial in chronic hepatitis delta has hit its primary endpoint, giving the biotech the first piece of the package it needs to file for FDA approval next year.
    fiercebiotech · 8d ago
  • Vir says hepatitis D drug combination succeeds in first pivotal study
    Vir Biotechnology’s chronic hepatitis D treatment has succeeded in the first of three late-stage studies, stoking competition with Gilead and Mirum Pharmaceuticals. Vir said Sunday afternoon that 4…
    endpoints · 8d ago
  • GSK, Ionis hepatitis B functional cure breaks open market for followers
    The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.
    biospace · 25d ago
  • Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
    Mirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patient…
    endpoints · 1mo ago
  • PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
    A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
    biopharma_dive · 1mo ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?